InMed Pharmaceuticals Inc. (NASDAQ:INM) Short Interest Down 25.1% in February

InMed Pharmaceuticals Inc. (NASDAQ:INM) was the recipient of a significant decline in short interest in February. As of February 28th, there was short interest totalling 26,900 shares, a decline of 25.1% from the February 13th total of 35,900 shares. Based on an average daily volume of 462,300 shares, the short-interest ratio is presently 0.1 days. Currently, 3.8% of the company’s stock are short sold.

InMed Pharmaceuticals Stock Down 2.8 %

InMed Pharmaceuticals stock opened at $2.74 on Tuesday. The stock has a market cap of $3.31 million, a PE ratio of -0.20 and a beta of 0.18. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.05 and a quick ratio of 2.44. The stock’s fifty day moving average is $3.44 and its two-hundred day moving average is $4.42. InMed Pharmaceuticals has a 1-year low of $2.41 and a 1-year high of $15.70.

InMed Pharmaceuticals (NASDAQ:INM) last issued its earnings results on Wednesday, February 12th. The company reported ($3.64) earnings per share for the quarter. InMed Pharmaceuticals had a negative return on equity of 90.74% and a negative net margin of 163.75%.

InMed Pharmaceuticals Company Profile

InMed Pharmaceuticals Inc, a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry.